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a  b  s  t  r  a  c  t
Inorganic  metalloids,  such  as arsenic  (As),  antimony  (Sb),  selenium  (Se),  and  tellurium  (Te),
are methylated  in  biota.  In  particular,  As,  Se,  and  Te  are  methylated  and  excreted  in urine.
The  biomethylation  is thought  to be  a  means  to detoxify  the  metalloids.  The  methylation
of  As  is  catalyzed  by  arsenic  (+3 oxidation  state)  methyltransferase  (AS3MT).  However,  it
is still  unclear  whether  AS3MT  catalyzes  the  methylation  of  the  other  metalloids.  It is  also
unclear  whether  other  factors  catalyze  the  As  methylation  instead  of  AS3MT.  Recombi-
nant  human  AS3MT  (rhAS3MT)  was  prepared  and used  in  the  in  vitro methylation  of As,
Se,  and  Te.  As, but not  Se  and  Te, was  speciﬁcally  methylated  in the  presence  of rhAS3MT.
Then,  siRNA  targeting  AS3MT  was  introduced  into  human  hepatocarcinoma  (HepG2)  cells.
Although AS3MT  protein  expression  was  completely  silenced  by  the gene  knockdown,  noCP–MS increase  in As  toxicity  was  found  in  the HepG2  cells  transfected  with  AS3MT-targeting
siRNA.  We  conclude  that  AS3MT  catalyzes  the methylation  of  As and  not  other  biomethy-
latable  metalloids,  such  as  Se  and  Te. We  speculate  that  other  methylation  enzyme(s)  also
catalyze the methylation  of As  in HepG2  cells.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
A metalloid is an element that has properties in between
hose of metals and non-metals. This unique character-
stic makes metalloids a valuable material in industry. In
articular, arsenic (As), antimony (Sb), selenium (Se), and
ellurium  (Te) have found various uses. In the periodic
Abbreviations: AS3MT, arsenic (+3 oxidation state) methyl-
ransferase; MMAsV, monomethylarsonic acid; ICP–MS, inductively
oupled plasma–mass spectrometry; DMAsV, dimethylarsinic acid;
AM, S-adenosyl-l-methionine; TMSe, trimethylselenonium ion; TMTe,
rimethyltelluronium ion.
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http://creativecommons.org/licenses/by-nc-nd/3.0/).table, As and Sb belong to group 15, and Se and Te belong
to  group 16. In addition, As and Se are in the fourth period,
and  Sb and Te are in the ﬁfth period. Enzymes that require
Se  in the form of selenocysteine are known; thus, Se is an
essential  element in animals. Enzymes that require As, Sb,
and  Te have not been identiﬁed so far.
As is used as a wood preservative, a pesticide, a glass
clarifying agent, and a material for semiconductors. In addi-
tion,  arsenic trioxide is used as a therapeutic agent for acute
promyelocytic leukemia [1]. On the other hand, inorganic
As  compounds are carcinogenic, and As environmental
pollution has attracted attention worldwide [2]. Sb is a
rare  metal that is used as a ﬂame retardant in textile, an
ingredient in paint, and a component of batteries. Like As,
inorganic Sb compounds are more hazardous than organic
Sb  compounds. Antimony trioxide is classiﬁed in group 2B
is is an open access article under the CC BY-NC-ND license
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[3].  Se is also widely used in industry, and is an essential
trace element in human. Se deﬁciency causes such health
problems as myocardial necrosis [4]. Meanwhile, the inges-
tion  of excess amounts of Se causes Se toxicosis, which is
characterized by vomiting, diarrhea, and muscle cramps
[5].  Te is a rare metal that is used in phase-change digital
versatile discs, solar panels, and Peltier devices. As the clin-
ical  symptoms of Te toxicity, garlic breath, vomiting, and
pigmentation of the oral mucosa are reported [6]. Although
those  metalloids are indispensable for human life, they may
pose  serious problems to human health and the environ-
ment.
In  animals, inorganic As is primarily transformed into
methylated metabolites, such as monomethylarsonic acid
(MMAsV) and dimethylarsinic acid (DMAsV). The enzyme
catalyzing the methylation is arsenic (+3 oxidation state)
methyltransferase (AS3MT) [7]. Sb, which belongs to the
same  group as As, is methylated not in animals but in
microorganisms [8]. Sb is excreted in urine as coordi-
nated compounds with organic anions, such as citrate
[9].  In contrast, Se and Te are biomethylatable species
in animals. Inorganic Se ingested in human and ani-
mals is primarily excreted in urine as selenosugars, e.g.,
Se-methylseleno-N-acetylgalactosamine [10,11]. Urinary
selenosugars are methylated compounds. In addition to
selenosugars, trimethylselenonium ion (TMSe) is also a uri-
nary  Se metabolite [12]. TMSe is excreted in urine when
the  amount of Se ingested exceeds the nutritional level
[13].  Te is also excreted in urine as trimethyltelluronium
ion (TMTe) [14,15]. Interestingly, no Te-containing sug-
ars,  tellurosugar, have been identiﬁed in urine so far. The
mechanisms underlying the methylation of the group 16
metalloids, i.e., Se and Te, are still unclear. Recombinant
AS3MTs was prepared from rat [16], human [17,18] and
alga  [19] genes, and their function and enzymatic char-
acteristics were evaluated. However, the involvement of
AS3MT  in the biomethylation of other metalloids has not
been  evaluated, yet. Hence, the aim of this study is to exam-
ine  whether AS3MT can catalyze the methylation of Se and
Te  or not. We  also evaluate whether AS3MT is a speciﬁc fac-
tor  for As methylation or not. Then, we attempt to clarify
the  characteristics of AS3MT in the metalloid methylation.
2. Materials and methods
2.1.  Reagents
Phosphate-buffered saline (PBS) (−) and primers
for PCR were purchased from Life Technologies (Carls-
bad, CA, USA). Bovine serum albumin (BSA), Trizma®
base (tris(hydroxymethyl)aminomethane), l-glutathione
reduced form (GSH), and catalase were purchased from
Sigma-Aldrich (St. Louis, MO,  USA). -Mercaptoethanol
(-ME) and S-adenosyl-l-methionine (SAM) were pur-
chased from Nacalai Tesque (Kyoto, Japan) and Zymo
Research (Irvine, CA, USA), respectively. Bacto Tryptone,
Bacto Yeast Extract, and Bacto Agar were purchased
from Becton, Dickinson and Company (Franklin Lakes,
NJ,  USA). TMSe was purchased from Tri Chemical Labora-
tories (Yamanashi, Japan). TMTe was synthesized in oureports 1 (2014) 589–595
laboratory  [20]. Monomethyltellurous acid was provided
by  Otsuka Chemical Co., Ltd. (Tokyo, Japan). Sodium
arsenite (iAsIII), disodium hydrogen arsenate heptahydrate
(iAsV), DMAsV, sodium tellurite (iTeIV), sodium tellurate
(iTeVI), and other reagents were purchased from Wako
Pure Chemical Industries (Osaka, Japan).
2.2. Cell culture
Human hepatocarcinoma cells, HepG2 cells, were
obtained from Riken BioResource Center (Tsukuba, Japan).
The  HepG2 cells were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM, Sigma-Aldrich) containing 10%
fetal  bovine serum (FBS; Hana-Nesco Bio, Tokyo, Japan)
and  100 U/mL penicillin plus 100 g/mL streptomycin (Life
Technologies) at 37 ◦C under a humid atmosphere of 5%
CO2.
2.3. Preparation of histidine-tagged recombinant human
AS3MT (rhAS3MT)
Total  RNA was  extracted from the HepG2 cells by means
of  a ReliaPrep RNA Cell Miniprep System (Promega, Madi-
son,  WI,  USA), and cDNA was  prepared from 2 g of
the total RNA using a High Capacity cDNA Reverse Tran-
scription Kit (Life Technologies). AS3MT cDNA lacking the
termination codon was  ampliﬁed by PCR with TaKaRa
Ex  Taq (1000 U) (Takara Bio, Shiga, Japan) and 10 M
primers (sense: 5′-ATGGCTGCACTTCGTGAC-3′, antisense:
5′-GCAGCTTTTCTTTGTGCCAC-3′). The PCR conditions were
as  follows: denaturation at 94 ◦C for 5 min; 30 cycles of
denaturation at 94 ◦C for 1 min, annealing at 64 ◦C for
1  min, and extension at 72 ◦C for 1 min; and a ﬁnal exten-
sion at 72 ◦C for 7 min. The PCR product was  inserted
into pBAD vector located downstream of the arabinose-
responsive element, and fused with six repeated histidine
(His)  elements for tagging using a pBAD TOPO TA Expres-
sion  Kit (Life Technologies) for 10 min  at room temperature.
pBAD-inserted rhAS3MT (pBAD-AS3MT) was  cloned in
competent Escherichia coli, DH10B, according to the man-
ufacturer’s instructions. The DH10B cells were cultured in
SOC  medium (Life Technologies) at 37 ◦C with gentle shak-
ing  at 190 rpm for 1 h, and then, the transformed DH10B
cells were selected in Luria-Bertani (LB) agar medium con-
taining  1% Bacto Tryptone, 0.5% Yeast Extract, 1% NaCl,
and  1.5% Bacto Agar with 0.1 mg/mL  ampicillin (Wako Pure
Chemical  Industries) at 37 ◦C overnight.
DH10B  cells transformed with pBAD-rhAsS3MT were
pre-incubated in 5 mL  of LB medium containing 0.1 mg/mL
ampicillin at 37 ◦C overnight with gentle shaking at
190  rpm. Then, a 5 mL  aliquot of the cell suspension was
cultured in 500 mL  of LB medium containing 0.1 mg/mL
ampicillin at 37 ◦C for 2.5 h with gentle shaking at 190 rpm.
After  the incubation, 2% l-(+)-arabinose (Sigma-Aldrich)
was  added to induce rhAsS3MT protein for 4 h. Then, the
cells  were collected and homogenized by sonication. The
homogenate was  centrifuged at 39,000 × g for 20 min.
His-tagged rhAS3MT protein in the supernatant was
puriﬁed by a nickel afﬁnity column (His GraviTrap, GE
Healthcare). The eluate was  dialyzed with Slide-A-Lyzer
Dialysis Cassettes (Thermo Fisher Scientiﬁc, Waltham, MA,
M. Tokumoto et al. / Toxicology Reports 1 (2014) 589–595 591
Table 1
HPLC  conditions for the separation of metalloid metabolites catalyzed by rhAS3MT.
Metalloid As Se and Sb Te
Column PRP X-100 GS-320HQ ES-502N 7C
(Hamilton; Reno, NV, USA) (Shodex; Tokyo, Japan) (Shodex; Tokyo, Japan)
Separation  mode Anion exchange Multi-mode size exclusion Anion exchange
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hColumn size (mm) 4.6 i.d. × 150 7.5 i.d. × 300
Flow rate (mL/min) 0.8 
Eluent 50 mM ammonium acetate (pH 6
SA). The quality and quantity of rhAS3MT were evaluated
y  Western blotting, as discussed below.
.4. In vitro methylation of metalloids and speciation
nalysis of methylated metabolites by LC–ICP–MS
The assay mixture consisted of 7 mM GSH, 1 mM SAM
s  the methyl group donor, 1 M metalloid, such as iAsIII,
SeIV, iSbIII, or iTeIV, and 30 g of rhAS3MT in 20 mM sodium
hosphate buffer. The assay mixture was incubated at
7 ◦C for 4 h, and then heated at 95 ◦C for 5 min  to ter-
inate the reaction. H2O2 was added to the mixture at
he  ﬁnal concentration of 3%, and the mixture was fur-
her  incubated for 1 h. Then, 50-fold diluted catalase was
dded  to eliminate excess H2O2 from the mixture. The mix-
ure  was centrifuged at 14,000 × g for 30 min, and ﬁltered
hrough a 0.45-m membrane ﬁlter. A 50 L aliquot of the
ltrate  was applied to an HPLC (Prominence, Shimadzu,
yoto, Japan) coupled with an inductively coupled plasma
ass  spectrometer (ICP–MS; 7500ce, Agilent Technologies,
achioji, Japan). The columns used for the separation of
ach  metalloid are shown in Table 1. As, Se, Sb, and Te in
he  eluate were detected by ICP–MS at m/z  75, 82, 121, and
30,  respectively.
.5.  AS3MT gene knockdown by siRNA
HepG2 cells were plated at 3 × 10 cells/cm2 and cul-
ured for 24 h. siRNA targeting AS3MT or control siRNA
as  introduced into the HepG2 cells at the ﬁnal con-
entration of 100 nM with Lipofectamine RNAiMAX (ﬁnal
oncentration: 0.3%; Life Technologies), and the cells
ere  incubated in Opti-MEM I (Life Technologies) for
0  min  at room temperature. The siRNA targeting AS3MT
nd  the control siRNA were as follows: AS3MT siRNA,
′-GAAGUAGCCCUAAGAUAUUTT-3′; and control siRNA, 5′-
UCCGUCUCGAAAGAGUUUAGUCCU-3′.
.6. Real-time RT–PCR
Total  RNA was extracted and cDNA was synthe-
ized by the same methods as those mentioned above
rom siRNA-treated HepG2 cells. Real-time PCR was car-
ied  out using Power SYBR Green Master Mix  (Life
echnologies) on an Applied Biosystems StepOne Real-
ime  PCR System (Life Technologies) according to
he  manufacturer’s instructions. Speciﬁc primers for
S3MT (sense, 5′-GCCTTGCAAAATGTACACGAA-3′; anti-
ense,  5′-TGCCACTTCCACTACCCAGA-3′) and glyceralde-
yde 3-phosphate dehydrogenase (GAPDH) serving as7.5 × 150
0.6 1.0
← 15 mM citric acid (pH 2.0)
control  (sense, 5′-GCACCGTCAAGGCTGAGAAC-3′; anti-
sense,  5′-TGGTGAAGACGCCAGTGGA-3′) were used.
2.7.  Western blot analysis
HepG2  cells treated with each siRNA were washed
with ice-cold PBS(−) and collected with 50 mM Tris–HCl
(pH 7.4). The pellets were homogenized by sonication for
15  min, and then centrifuged at 105,000 × g for 1 h. A 20 g
portion  of protein in the supernatant was separated by
SDS-PAGE, and then transferred onto polyvinylidene ﬂu-
oride  membrane (Hybond-P, GE Healthcare) at 20 V for
1  h. The membrane was  blocked for 1 h with 3% BSA in
PBS(−)  containing 0.1% Tween-20 (PBS-T). For the detec-
tion  of AS3MT, the membrane was  washed brieﬂy with
PBS-T  and incubated with anti-Cyt19 (AS3MT) rabbit poly-
clonal  antibody (1:1000) (Santa Cruz Biotechnology, Dallas,
TX,  USA) diluted 100-fold with PBS-T containing 5% BSA
overnight at 4 ◦C. The membrane was washed with PBS-T,
and  probed with horseradish-peroxidase-conjugated anti-
rabbit  IgG (1:50,000) (GE Healthcare). The bands were
visualized with Immobilon Western Chemiluminescent
Substrate (Merck Millipore, Billerica, MA,  USA) and LAS-
1000  UV mini (FUJIFILM, Tokyo, Japan). For the detection
of  rhAS3MT, anti-His-tag antibody (GE Healthcare) was
also  used as the primary antibody in addition to anti-
Cyt19 antibody. Anti-GAPDH mouse polyclonal antibody
(Santa Cruz Biotechnology) and horseradish-peroxidase-
conjugated anti-mouse IgG (GE Healthcare) were used for
the  detection of GAPDH.
2.8.  Assay for cytotoxicity
HepG2  cells were seeded in a 96-well plate. HepG2 cells
treated with AS3MT or control siRNA were treated with
0.1,  0.5, 1.0, 5, 10, 50, 100, 500, and 1000 M iAsIII, iSeIV
or iTeIV in FBS-free medium for 24 h. After the incuba-
tion, the medium was discarded and the cells were washed
twice  with PBS(−). The cells were subjected to CellTiter 96
AQueous  One Solution Cell Proliferation Assay (Promega)
for  4 h, and cell viability was  determined by measuring the
absorbance at 490 nm.
2.9. Statistical analysis
Data  are presented as means ± standard deviation (S.D.)
of  three to four independent experiments. Statistical anal-
yses  were performed using one-way analysis of variance
followed by Bonferroni-type multiple t-test. Differences
between the groups were signiﬁcant at p < 0.05.
ology Reports 1 (2014) 589–595
Fig. 1. Elution proﬁle of As in the assay mixture. The assay mixture
consisted of 7 mM GSH, 1 mM SAM as the methyl group donor, and 1 M
iAsIII in 20 mM sodium phosphate buffer in the presence (B) or absence (A)
of  30 g of rhAS3MT. The assay mixture was incubated at 37 ◦C for 4 h, and
then heated at 95 ◦C for 5 min  to terminate the reaction. H2O2 was added
to the mixture at the ﬁnal concentration of 3%, and further incubation was
carried out for 1 h. Then, 50-fold diluted catalase was added to eliminate
excess H2O2 from the mixture. A 50 L aliquot of the ﬁltrate was applied to592 M. Tokumoto et al. / Toxic
3. Results and discussion
3.1.  In vitro methylation of metalloids
The quantity and quality of rhAS3MT were examined
by Western blotting (data not shown). As the quantity
and quality were sufﬁcient, rhAS3MT was used for the lat-
ter  experiments. rhAS3MT catalyzed the methylation of
As,  which was proven by the appearance of novel peaks
of  As at the retention times of 3.4 and 3.8 min  (Fig. 1B).
That  the retention time of the former peak corresponded
to that of DMAsV standard suggested that rhAS3MT was
able  catalyze the methylation of arsenite in the presence
of  GSH and SAM (Fig. 1B and C). Although monomethy-
larsonic acid (MMAsV) standard was not available, the
latter  peak seemed to be MMAsV, a metabolic intermedi-
ate.
Only inorganic Se compounds, such as selenite (iSeIV)
and  selenate (iSeVI), were detected at the retention times
of  17.0 and 14.4 min, respectively, even in the presence
of rhAS3MT. TMSe, a urinary metabolite of Se, was not
detected (Fig. 2). Similar results were obtained for Te,
namely, no methylated metabolites, such as TMTe and
MMTe, were detected even in the presence of rhAS3MT
(Fig. 3B). Two minor peaks were detected at the retention
times of 2.1 and 2.4 min  in the presence and absence of
AS3MT  (Fig. 3A and 3B). Because the peaks were detected
even in the absence of AS3MT, it was speculated that those
Te  species were complexes with GSH or SAM. It is known
that  Se and Te are also methylated in vivo [14,21]. How-
ever,  our results suggest that AS3MT does not catalyze the
methylation of Se and Te. We  also found that rhAS3MT
did not catalyze the methylation of iSbIII in vitro (data
not shown). This observation is coincident with the fact
that  iSbIII is not methylated in vivo [22]. Consequently,
although inorganic As, Se, and Te are methylated in vivo,
AS3MT is speciﬁc to As. In bacteria, the methylation of
Se  and Te is catalyzed by thiopurine methyltransferase
(TPMT) [23]. TPMT is also found in mammals. Hence,
although we were unable to present direct evidence in
this  study, TPMT could be the responsible methyltrans-
ferase that catalyzes the methylation of Se and Te in
mammals.
3.2.  Effect of AS3MT gene knockdown on cytotoxicity of
metalloids
The  treatment with siRNA targeting AS3MT reduced
AS3MT mRNA expression to around 30% of control (Fig. 4A),
and  no apparent expression of AS3MT protein was detected
by  Western blotting (Fig. 4B). Hence, sufﬁcient effects of
siRNA  could be obtained under the experimental condi-
tions  adopted in this study.
The  viability of HepG2 cells transfected with AS3MT-
targeting siRNA was not signiﬁcantly different from that of
cells  transfected with control siRNA (Fig. 5). It is reason-
able that no differences are observed in the cell viability
between HepG2 cells transfected with AS3MT-targeting
and control siRNA against the Se and Te exposure, because
AS3MT does not contribute to the detoxiﬁcation, i.e., the
methylation of Se and Te, as shown in Figs. 2 and 3. InPRP  X-100, an anion exchange column. The eluate was directly introduced
to an ICP–MS to detect As at m/z  75. As standards, such as iAsIII , iAsV, and
DMAsV without treatment with H2O2, were also analyzed (C).
contrast, As was substantially methylated in the presence
of  AS3MT in vitro. However, the methylation catalyzed by
AS3MT  did not contribute to the detoxiﬁcation of As. Those
results  lead us to two speculations. First, the methylation is
not  a detoxiﬁcation process but a metabolic activation of As
M. Tokumoto et al. / Toxicology Reports 1 (2014) 589–595 593
Fig. 2. Elution proﬁle of Se in the assay mixture. The assay mixture
consisted of 7 mM GSH, 1 mM SAM as the methyl group donor, and 1 M
iSeIV in 20 mM sodium phosphate buffer in the presence (B) or absence (A)
of  30 g of rhAS3MT. The assay mixture was incubated at 37 ◦C for 4 h, and
then heated at 95 ◦C for 5 min  to terminate the reaction. H2O2 was added
to the mixture at the ﬁnal concentration of 3%, and further incubation was
carried out for 1 h. Then, 50-fold diluted catalase was added to eliminate
excess H2O2 from the mixture. A 50 L aliquot of the ﬁltrate was  applied to
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Fig. 3. Elution proﬁle of Te in the assay mixture. The assay mixture
consisted of 7 mM GSH, 1 mM SAM as the methyl group donor, and 1 M
iTeIV in 20 mM sodium phosphate buffer in the presence (B) or absence
(A) of 30 g of rhAS3MT. The assay mixture was incubated at 37 ◦C for 4 h,
and then heated at 95 ◦C for 5 min  to terminate the reaction. H2O2 was
added to the mixture at the ﬁnal concentration of 3%, and further incu-
bation was  carried out for 1 h. Then, 50-fold diluted catalase was added
to eliminate excess H2O2 from the mixture. A 50 L aliquot of the ﬁltrate
was applied to ES-502 N 7 C, an anion exchange column. The eluate wasS-320HQ, a multi-mode size exclusion column. The eluate was  directly
ntroduced to an ICP–MS to detect Se at m/z 82. Se standards, such as iSeIV,
SeVI, and TMSe without treatment with H2O2, were also analyzed (C).
oxicity. It has been reported that some harmful metabo-
IIIites, such as monomethylarsonous acid (MMAs ) and
imethylarsinous acid (DMAsIII), are formed by the meth-
lation of iAsIII [24]. Those trivalent methylated arsenicals
ossess comparable toxicity to iAsIII. Indeed, the IC50 valuesdirectly introduced to an ICP–MS to detect Te at m/z  130. Te standards,
such as iTeIV, MMTe, and TMTe without treatment with H2O2, were also
analyzed (C).
of iAsIII and DMAsIII in human epidermoid carcinoma A431
cells  were 5.49 and 2.16 M,  respectively [25]. In addition
to  the trivalent methylated arsenicals, such thioarseni-
cals as dimethylmonothioarsinic acid (DMMTAsV) and
dimethyldithioarsinic acid (DMDTAsV) are also reported as
594 M. Tokumoto et al. / Toxicology Reports 1 (2014) 589–595
Fig. 4. Effect of siRNA targeting AS3MT on AS3MT mRNA and pro-
tein expression. AS3MT mRNA and protein expression was analyzed by
real-time RT–PCR and Western blotting, respectively. Columns and bars
represent the means ± S.D. of the relative amounts of AS3MT mRNA for
three samples (A). The mRNA expression of AS3MT was normalized to
that  of GAPDH. Two typical blots of AS3MT protein are shown (B). N.T.;
Fig. 5. Effect of siRNA targeting AS3MT on the cytotoxicity of arsenite,
selenite, and tellurate. HepG2 cells were transfected with AS3MT-
targeting siRNA or control siRNA, and exposed to iAsIII (A), iSeIV (B), or
iTeIV (C) for 48 h after the transfection at concentrations of 0, 0.5, 1.0, 10,not transfected.
harmful metabolites of iAsIII even though they are penta-
valent species [26]. The IC50 values of DMMTAV in human
epidermoid carcinoma A431 cells and human bladder
carcinoma EJ-1cells were 10.7 and 16.7 M,  respectively
[25,27]. Consequently, the toxicity of iAsIII in AS3MT-
knockdown cells would be comparable to those of harmful
metabolites in control cells. However, DMAsV as the ﬁnal
metabolite is far less toxic than those harmful metabolites
because its IC50 in A431 cells is reported to be 843 M
[13]. Thus, this speculation seems to be less feasible than
the  next one. As our second speculation, AS3MT is not a
speciﬁc  factor for the methylation of As. AS3MT-KO mice
are  available and are known to be more sensitive to the
As  toxicity than wild-type mice [28,29]. Nonetheless, it
was  reported that the methylated metabolites of As were
detected in urine, liver, and kidney of even AS3MT-KO
mouse, although the amounts of the metabolites in AS3MT-
KO  mouse were less than those in wild-type mouse [28].
This  observation also suggested that AS3MT was not the
sole  factor catalyzing the methylation of As, i.e., other
enzyme(s) might exist. Indeed, it was reported that N-
6  adenine-speciﬁc DNA methyltransferase 1 (N6AMT1)
involved in the methylation of MMAsIII to DMA  although its
expression was relatively low comparing with AS3MT [30].
Future  studies should be conducted to entire mechanism
underlying the biomethylation of metalloids in cultured
cells.50, 70, 100, 300, 500, and 1000 M for 24 h. Values and bars indicate the
means ± S.D. for four samples.
4. Conclusions
AS3MT speciﬁcally catalyzes the methylation of As, and
is  not responsible for the methylation of other biomethy-
latable metalloids, such as Se and Te. Other methylation
enzyme(s) may  catalyze the methylation of As in HepG2
cells.
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